211At-BC8-B10 Followed by Donor Stem Cell Transplant
Phase 1/2
30
about 9.7 years
18–75
1 site in WA
What this study is about
This trial is testing the safety and best dose of a radioactive agent linked to an antibody (211At-BC8-B10) followed by donor stem cell transplant in treating patients with high-risk acute leukemia or myelodysplastic syndrome that has come back or isn't responding to treatment. The treatment involves giving chemotherapy, total body irradiation, and then donor stem cells to help the patient's bone marrow make new blood cells.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
- 2.Receive Recombinant Granulocyte Colony-Stimulating Factor
- 3.Receive Total-Body Irradiation
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), Antineoplastic Agent [TC] (Nucleic Acid Synthesis Inhibitors), Immunological Agents (Enzyme Inhibitors), colony stimulating factor, tacrolimus
infusion, injection (Injection), injection, intravenous
Primary: Toxicity: Proportion of patients who develop grades III/IV Bearman regimen-related toxicity
Secondary: Disease-free survival, Non-relapse mortality (NRM), Overall survival
biopsy, diagnostic, radiation
Oncology